Urology Times staff

“Probably one of the most meaningful findings was that insurance type did influence the choice of medication first prescribed by urologists for overactive bladder,” says Michelle E. Van Kuiken, MD.

“I believe that at this point in time, we should be able to offer our patients some options, to at least give them a sense of feeling that they're participating in this procedure, that they have some control over this procedure. I think nitrous oxide can provide that,” says Heidi J. Rayala, MD, PhD.

“So, we see that in [the] men who have sex with men population, they have a greater mental health burden from this disease as they report having a more negative experience with a urologist,” says Thairo Pereira, MD.

“The main rationale for this research was we felt like there was an unaddressed population of patients living with urinary incontinence,” says Nathan M. Shaw, MD.

“The bladder muscle can get weak as you get older, so developing urinary incontinence or ur-gency is very common as you get older,” says Vikas Desai, MD.

"I think that what most people will find is, if you're in an academic center, it can be a little bit difficult to set up a nitrous oxide program because there is a lot of red tape for bringing a gas into the ambulatory setting," says Heidi J. Rayala, MD, PhD.

“So, my take home message for the urology community is even if you're not doing clinical trials, we already have FDA-approved, CMS-covered, most commercial insurances-covered genetic alterations now for our CRPC populations, and there will be more to come,” says Neal D. Shore, MD, FACS.

“I think we should all be pretty selective in whom we're operating on in the metastasectomy setting,” says Harras B. Zaid, MD.

“As far as that point of max curve, I would say this is pretty definitive that this is something that needs to be done and changed within someone's practice,” says Landon Trost, MD.

"The study was done between April 2021 to 2023, so a 2-year span. It was surprising to find that 24% of our patients in that time span had opioid-free discharge," says Katherine Wang, MD.

Bogdana Schmidt, MD, MPH, outlines key bladder cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

“When it comes to this, I think having a great team around you is really so important,” says Bree Duncan, RN, BSN.

"Again, operating has more and more taken a backseat as the armamentarium of systemic medications, especially checkpoint inhibitors [and] combination treatments, has exploded," says Harras B. Zaid, MD.

“I love helping people to connect with their passions and to find and create the lives that they wish to create, both within the field of medicine and urology,” says Anne M. Suskind, MD, MS, FACS, FPMRS.

Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

“I think if you were to ask what surprised me, I didn't expect it to have more of an effect on pain than anxiety,” says Heidi J. Rayala, MD, PhD.

“What it brought up is the point that where the field seems to be going is incorporating the PET imaging and the MRI imaging, and maybe PET MRI,” says Michael S. Cookson, MD, MMHC, FACS.

“It's exhausting and it's overwhelming, but traction has been gained and continues to be gained and we are making some meaningful, tangible differences,” says Mara R. Holton, MD.

"Using the model of 100 implants per year, and assuming that we can reduce teaching visits by 1 during that 90-day global period, that translates into an estimated additional 3000 minutes of outpatient time that you have available to assist other patients," says Bradley Gill, MD.

In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.

“There has been a stage migration in part related to the availability of cross-sectional imaging, but there's still a proportion of patients who present with locally advanced disease,” says Harras B. Zaid, MD.

“I think being younger and going through something so scary, I think it's been really important to her to have someone with her throughout the whole process,” says Bree Duncan, RN, BSN.

"We're entering an era of more trauma-informed care, and trying to be sensitive to the fact that some of these invasive procedures can be a trigger for people because they're in that moment of feeling helpless and they don't have really a lot of control over the situation," says Heidi J. Rayala, MD.

"If you don't do a repeat curve assessment with each series of injections, you're possibly going to be missing the best location to do the injections," says Landon Trost, MD.

"The genomics assay was using biopsy tissue to help patients make decisions for the treatment choices. We also tested the effect of the assay on provider choice," says Adam B. Murphy, MD, MBA, MSCI.

"There are a lot of questions and issues regarding [topics] like body image and sexual function, and things like that, that also, being a woman in this role, I feel like they feel comfortable asking me those questions," says Bree Duncan, RN, BSN.

"Then [we] also started looking at somatic testing, because if you only stop at germline testing, you miss another 50% of patients who would have somatic alterations who have resistant prostate cancer," says Neal D. Shore, MD, FACS.

"In 2021, we started collecting data on opioids prescribed at discharge to see whether or not patients did or did not get prescribed opioids," says Katherine Wang, MD.

"My goal is to always meet them there in clinic, and then just start that relationship, in a sense of, I'm there for whatever they need," says Bree Duncan, RN, BSN.

“Private equity allows an opportunity to provide improved scale with large organization,” says Scott B. Sellinger, MD, FACS.